IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Barbara ENENKEL et al. U.S. Appln. No. : 10/724,301 Confirmation No. : 5533 U.S. Filing Date : November 26, 2003 Title of Invention : Neomycin-Phosphotranferas) Examiner: se-Genes and Me	
Recombinant Cells Producing Attny. Docket No.: 1/1411	High Levels of	a Desired Gene Product
Filed Via EFS Web Mail Stop RCE Commissioner for Patents Alexandria, VA 22313-1450		
Date: July 10, 2007		
TRANSMITTAL LETTER FOR INFORM	<u>1ATION DISCI</u>	LOSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject app Statement (Form 1449A/B) under 37 C.F.R. §§1 hereinbelow.		
1.97(b). This Statement is being fill date of a national application other than a continuous \$1.53 (d); ii) within three (3) months of the date 37 C.F.R. §1.491 in an international application; on the merits; or iv) before the mailing of a first continued examination under 37 C.F.R. §1.114.	ued prosecution a of entry of the na iii) before the m	application under 37 C.F.R. ational stage as set forth in ailing of a first Office action
1.97(c). This Statement is being fill C.F.R. §1.97(b), but before the mailing date of: i notice of allowance under 37 C.F.R. §1.311, or in action that otherwise closes prosecution in the accompanied by:) a final action u ii) a	nder 37 C.F.R. §1.113, ii) a
A statement as specified in 37 C.	F.R. §1.97(e) [se	ee below]; or
The fee set forth in 37 C.F.R. §1.1	17(p).	

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
§1.97(c	97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	97(e).
	Each item of information contained in the instant information disclosure attement was first cited in any communication from a foreign patent office in a punterpart foreign application not more than three (3) months prior to the filing of e instant information disclosure statement; or
	No item of information contained in the instant information disclosure attement was cited in a communication from a foreign patent office in a counterpart reign application, and, to the knowledge of the person signing this certification after aking reasonable inquiry, no item of information contained in the instant formation disclosure statement was known to any individual designated in 37 F.R. §1.56(c) more than three (3) months prior to the filing of the instant formation disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosu counter in section	704(d). Each item of information contained in the accompanying information e statement was first cited in any communication from a foreign patent office in a art application, which communication was not received by any individual designated 1.56(c) more than thirty (30) days prior to the filing of the accompanying on disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Respectfully submitted,

/Edouard G. Lebel/ Edouard G. Lebel Agent for Applicants Reg. No. 43,742

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 778-7635

Date: July 10, 2007

Fax: (203) 798-4408